A study involving 105 ovarian cancer patients found that 76% of patients with homologous recombination deficiency (HRd) treated with bevacizumab and PARP inhibitors had a progression-free survival (PFS) of 18 months, significantly higher than the 47% observed in the HRd-negative group. This evidence concerns the gene PARP1 and ovarian cancer.